1. Glabridin may serve as an anti-inflammatory agent in diabetes-related vascular dysfunction,through regulating the synthesis and activity of iNOS under high-glucose levels; may possess a therapeutic effect on metabolic disorders( such as diabetes and hyperglycemia), by modulating glucose metabolism through AMPK in skeletal muscle cells.
2. Glabridin may have potential as a chemopreventive agent against liver cancer metastasis, by inhibiting the invasion of human HCC cells.
1. Ginsenosides Rg3 suppressed swelling of oxazolone-induced mouse ear contact dermatitis.
2. Ginsenosides Rg3 induced differentiation of HL-60 cells into granulocytes and modulation of PKC isoform levels.
3. Ginsenosides Rg3 inhibited LPS-induced iNOS and cytokine expressions.
4. Ginsenosides Rg3 is a potential therapeutic modality for neurodegenerative diseases by inhibiting microglial activation.
1. Kurarinone shows weak estrogenic activity both in the yeast screen and in the Ishikawa Var-I assay with EC(50) values of 4.6 and 1.66 microM, respectively; kurarinone also has potent cytotoxic activity (IC(50) value = 22.2 microM) against human MCF-7/6 breast cancer cells.
2. Kurarinone exhibits strong inhibitory effect on immune responses, kurarinone may ameliorate chronic inflammatory skin diseases through the suppression of pathogenic CD4(+) T-cell differentiation and the overall immune response.
3. Kurarinone sensitizes TNF-related apoptosis inducing ligand (TRAIL)-induced tumor cell apoptosis via suppression of NF-κB-dependent cFLIP expression, indicating that this compound can be used as an anti-tumor agent in combination with TRAIL.
4. Kurarinone combined with interferon a-lb (IFNalpha-1b) shows better effect in treating chronic hepatitis B than that of using either of the two alone.
5. Kurarinone may be by way of down-regulating Smad3 expression to interfere its induction on intercellular signal transduction and consequently ameliorate renal interstitial fibrosis.
1. 1beta-Hydroxyalantolactone has protective effect against AD-like skin inflammation, can as a potential therapeutic agent for AD.
1. 14-Deoxyandrographolide desensitizes hepatocytes to TNF-alpha-mediated apoptosis through the release of TNFRSF1A.
2. 14-Deoxyandrographolide has hepatoprotective activity, mediates activation of adenylate cyclase-cAMP signaling leading to up-regulation of cNOS, may provide a promising approach in the prevention of liver diseases during chronic alcoholism.